ArticleAmerican journal of nuclear medicine and molecular imaging2016
Prognostic value of FDG PET/CT-based metabolic tumor volumes in metastatic triple negative breast cancer patients.
Article in American journal of nuclear medicine and molecular imaging, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The impact of PET imaging on triple negative breast cancer: an updated evidence-based perspective.European journal of nuclear medicine and molecular imaging · 2024Pooled it
- Pooled it
- Analysis of the StoRM cohort reveals physical activity to be associated with survival in metastatic breast cancer.Scientific reports · 2020Trial
- Prognostic value of 18F-choline PET/CT metabolic parameters in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide.European journal of nuclear medicine and molecular imaging · 2018Trial
- The anatomical distribution of metabolic tumor burden provides prognostic information beyond whole-body ¹⁸F-FDG PET/CT metrics in de novo metastatic HER2-positive breast cancer.Annals of nuclear medicine · 2026Article
- Prognostic relevance of [18F]FDG PET/CT in triple-negative breast cancer: Results from the triple negative (TRINE)-PET trial.European journal of nuclear medicine and molecular imaging · 2026Article
- Do new guidelines enable a more accurate comparison of [Breast cancer research : BCR · 2026Article
- Integrating PET/CT-derived heterogeneity indices and composite risk scores improves prognostic stratification in breast cancer.European journal of nuclear medicine and molecular imaging · 2026Article
- Prognostic Implications of Volume-based Quantitative 18F-FDG PET/CT Biomarkers in Pulmonary Sarcoidosis.Clinical nuclear medicine · 2026Article
- Multi-omics deep learning improves FDG PET-CT-based long-term prognostication of breast cancer.NPJ precision oncology · 2026Article
- FDG PET/CT in the post-treatment evaluation of breast cancer: an emphasis on triple-negative breast cancer.American journal of nuclear medicine and molecular imaging · 2026Review
- Response-adaptive breast cancer care in the grey zones: integrating ER and HER2 targeted PET, FDG PET/CT under immunotherapy, and ctDNA kinetics.Exploration of targeted anti-tumor therapy · 2026Review
- Pre-treatment [18F]FDG PET/CT biomarkers for the prediction of antibody-drug conjugates efficacy in metastatic breast cancer.European journal of nuclear medicine and molecular imaging · 2025Article
- Prognostic significance ofAnnals of nuclear medicine · 2024Article
- Review
- Added prognostic value of molecular imaging parameters over proliferation index in typical lung carcinoid: an [18F]FDG PET/CT and SSTR imaging study.Annals of nuclear medicine · 2023Article
- Prognosis Associated with Glycolytic Activity in Regional Lymph Nodes of Patients with Previously Untreated Metastatic Breast Cancer: A Preliminary Study.Diagnostics (Basel, Switzerland) · 2022Article
- Heterogeneity derived fromCancer medicine · 2022Article
- Facts and Perspectives: Implications of tumor glycolysis on immunotherapy response in triple negative breast cancer.Frontiers in oncology · 2022Review
- Prediction of Neoadjuvant Chemotherapy Response in Osteosarcoma Using Convolutional Neural Network of Tumor CenterDiagnostics (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
FDG PET/CT-based measures of tumor burden show promise to predict survival in patients with metastatic breast cancer, but the patient populations studied so far are heterogeneous. The reports may have been confounded by the markedly different prognosis of the various subtypes of breast cancer. The purpose of this study is to evaluate the correlation between tumor burden on FDG PET/CT and overall survival (OS) in patients within a defined population: metastatic triple negative breast cancer (MTNBC). FDG PET/CT scans of 47 consecutive MTNBC patients (54±12 years-old) with no other known malignancies were analyzed. A total 393 lesions were identified, and maximum standardized uptake value (SUVmax), mean SUV, metabolic tumor volume (MTV), total lesion number (TLN) and total lesion glycolysis (TLG), were measured and correlated with patient survival by Mantel-Cox tests and Cox regression analysis. At a median follow-up time of 12.4 months, 41 patients died with a median OS of 12.1 months. Patients with MTV less than 51.5 ml lived nearly three times longer (22 vs 7.1 months) than those with a higher MTV (χ(2)=21.3, P<0.0001). In a multivariate Cox regression analysis only TLN and MTV were significantly correlated with survival. Those with an MTV burden in the 75(th) percentile versus the 25(th) percentile had a hazard ratio of 6.94 (p=0.001). In patients with MTNBC, MTV appears to be a strong prognostic factor. If validated in prospective studies, MTV may be a valuable tool for risk stratification of MTNBC patients in clinical trials and to guide patient management.
Indexed as
Identifiers
27186439PMC4858608What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.